Detection of a large rearrangement in PALB2 in Spanish breast cancer families with male breast cancer

It has been demonstrated that monoallelic PALB2 (Partner and Localizer of BRCA2) gene mutations predispose to familial breast cancer. Some of the families reported with germline PALB2 mutations presented male breast cancer as a characteristic clinical feature. Therefore, we wanted to investigate the...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Breast cancer research and treatment 2012-02, Vol.132 (1), p.307-315
Hauptverfasser: Blanco, Ana, de la Hoya, Miguel, Balmaña, Judith, Ramón y Cajal, Teresa, Teulé, Alex, Miramar, María-Dolores, Esteban, Eva, Infante, Mar, Benítez, Javier, Torres, Asunción, Tejada, María-Isabel, Brunet, Joan, Graña, Begoña, Balbín, Milagros, Pérez-Segura, Pedro, Osorio, Ana, Velasco, Eladio A., Chirivella, Isabel, Calvo, María-Teresa, Feliubadaló, Lidia, Lasa, Adriana, Díez, Orland, Carracedo, Angel, Caldés, Trinidad, Vega, Ana
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:It has been demonstrated that monoallelic PALB2 (Partner and Localizer of BRCA2) gene mutations predispose to familial breast cancer. Some of the families reported with germline PALB2 mutations presented male breast cancer as a characteristic clinical feature. Therefore, we wanted to investigate the contribution of germline PALB2 mutations in a set of 131 Spanish BRCA1/BRCA2 -negative breast/ovarian cancer families with at least one male breast cancer case. The analysis included direct sequencing of all coding exons and intron/exon boundaries as well as a Multiplex Ligation-dependent Probe Amplification-based analysis of genomic rearrangements. For the first time we have identified a genomic rearrangement of PALB2 gene involving a large deletion from exon 7 to 11 in a breast cancer family. We have also identified several PALB2 variants, but no other obvious deleterious PALB2 mutation has been found. Thus, our study does not support an enrichment of PALB2 germline mutations in the subset of breast cancer families with male breast cancer cases. The identification of intronic and exonic variants indicates the necessity of assessing the implications of variants that do not lead to PALB2 truncation in the pathoghenicity of the PALB2 gene.
ISSN:0167-6806
1573-7217
DOI:10.1007/s10549-011-1842-2